Varv A, Kalata B1 [T20S]
General Information
DCTPep ID DCTPep00071
Peptide Name Varv A, Kalata B1 [T20S]
Sequence GLPVCGETCVGGTCNTPGCSCSWPVCTRN
Sequence Length 29
UniProt ID P58458 P58446 P85525 Q5USN7 B5B3Z7 B6E615 B5B3Z3 B5B3Z4 M9T7B1
PubChem CID Not available
Origin Viola arvensis (European field pansy) (Field violet)
Type Native peptide
Classification
ACP Tumor active peptide Membrane-targeted
Activity Information
Cell Line | Disease | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|
HeLa | Human papillomavirus-related endocervical adenocarcinoma | CC50=16.1±0.4 μM | Resazurin assay | 2, 24 h | 4 |
MM96L | Melanoma | CC50=17.9±0.7 μM | Resazurin assay | 2, 24 h | 4 |
K562 | Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia | CC50=9.5±0.2 μM | Resazurin assay | 2, 24 h | 4 |
CLL (Primary Human Cells) | Chronic lymphocytic leukemia | IC50=1.34 µM | FMCA assay | 72h | 1 |
OVCA (Primary Human Cells) | Ovarian carcinoma | IC50=11.03 µM | FMCA assay | 72h | 1 |
RPMI-8226/Dox40 | Plasma cell myeloma; Multiple myeloma | IC50=2.73 µM | FMCA assay | 72h | 1 |
RPMI-8226/LR-5 | Plasma cell myeloma; Multiple myeloma | IC50=3.19 µM | FMCA assay | 72h | 1 |
RPMI-8226/s | Plasma cell myeloma; Multiple myeloma | IC50=3.24 µM | FMCA assay | 72h | 1 |
CCRF-CEM | Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia | IC50=3.56 µM | FMCA assay | 72h | 1 |
U251 | Astrocytoma | IC50=37.18 µg/ml | SRB assay | 48h | 2 |
ACHN | Papillary renal cell carcinoma; Papillary renal cell carcinoma | IC50=4.19 µM | FMCA assay | 72h | 1 |
U-937/Vcr | Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia | IC50=4.84 µM | FMCA assay | 72h | 1 |
NCI-H69 | Lung small cell carcinoma; Small cell lung cancer | IC50=4.88 µM | FMCA assay | 72h | 1 |
NCI-H69AR | Lung small cell carcinoma; Small cell lung cancer | IC50=4.89 µM | FMCA assay | 72h | 1 |
CCRF-CEM/VM-1 | Not available | IC50=4.97 µM | FMCA assay | 72h | 1 |
U-937/GTB | Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia | IC50=6.35 µM | FMCA assay | 72h | 1 |
A549 | Lung adenocarcinoma | IC50>10 µg/ml | SRB assay | 48h | 2 |
BEL-7402 | Human papillomavirus-related endocervical adenocarcinoma | IC50>10 µg/ml | SRB assay | 48h | 2 |
DU145 | Prostate carcinoma | IC50>10 µg/ml | SRB assay | 48h | 2 |
MDA-MB-231 | Breast adenocarcinoma | IC50>10 µg/ml | SRB assay | 48h | 2 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity PBMC: IC50=12.13 µM
Target Not available
Affinity Not available
Mechanism Not available
Structure Information
PDB ID Not available
Predicted Structure DCTPep00071
(Please note that there is the predicted structure, predicted by AlphaFold)
Helicity Not available
Linear/Cyclic Cyclic
Disulfide/Other Bond Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asn29
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C116H185N35O40S6
Absent amino acids ADFHIKMQY
Theoretical pI 5.96
Acidic residues 1
Basic residues 1
Polar residues 19
Molecular weight (Average) 2902.32
Molecular weight (Monoisotopic) 2900.18
Common amino acids C
Net charge 0
Instability index (II) 46.59
Aliphatic index 43.45
Grand average of hydropathicity (GRAVY) 0.148
Half Life
30 hours (mammalian reticulocytes, in vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).
Extinction coefficients
Ext. coefficient 5875
Abs 0.1% (=1 g/l) 2.024, assuming all pairs of Cys residues form cystines
Ext. coefficient 5500
Abs 0.1% (=1 g/l) 1.895, assuming all Cys residues are reduced
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 12477048
Title Cyclotides: a novel type of cytotoxic agents
Doi 10.1097/00008390-200204000-00013
Year 2002
Literature 2
Pubmed ID 20580652
Title Isolation and characterization of cytotoxic cyclotides from Viola tricolor
Doi 10.1016/j.peptides.2010.05.004
Year 2010
Literature 3
Pubmed ID 10600388
Title Plant cyclotides: A unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif
Year 1999
Literature 4
Pubmed ID 25099014
Title Anticancer and toxic properties of cyclotides are dependent on phosphatidylethanolamine phospholipid targeting
Year 2014
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available